Initial testing (stage 1) of the notch inhibitor PF-03084014, by the pediatric preclinical testing program

Pediatric Blood and Cancer

Volumn 61, Issue 8, 2014, Pages 1493-1496

  Carol, Hernan ^a   Maris, John M ^b   Kang, Min H ^c   Reynolds, C Patrick ^c   Kolb, E Anders ^d   Gorlick, Richard ^e   Keir, Stephen T ^f   Wu, Jianrong ^g   Kurmasheva, Raushan T ^h   Houghton, Peter J ^h   Smith, Malcolm A ⁱ   Lock, Richard B ^a  

^a CHILDREN S CANCER INSTITUTE AUSTRALIA FOR MEDICAL RESEARCH   (Australia)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^d NEMOURS ALFRED I DUPONT HOSPITAL FOR CHILDREN   (United States)

^e CHILDREN S HOSPITAL AT MONTEFIORE   (United States)

^f DUKE UNIVERSITY MEDICAL CENTER   (United States)

^g ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^h NATIONWIDE CHILDREN S HOSPITAL   (United States)

ⁱ NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Developmental therapeutics; Notch inhibitors; Preclinical testing

Indexed keywords

GAMMA SECRETASE; PF 3084014;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; EWING SARCOMA; GLIOBLASTOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MAXIMUM TOLERATED DOSE; MOUSE; NEUROBLASTOMA; NONHUMAN; OSTEOSARCOMA; PRIORITY JOURNAL; RHABDOID TUMOR; RHABDOMYOSARCOMA; SOLID TUMOR; TUMOR VOLUME; TUMOR XENOGRAFT;

DEVELOPMENTAL THERAPEUTICS; NOTCH INHIBITORS; PRECLINICAL TESTING;

ANIMALS; ANTINEOPLASTIC AGENTS; CHILD; CHILD, PRESCHOOL; HUMANS; MICE, INBRED BALB C; MICE, NUDE; MICE, SCID; NEOPLASM PROTEINS; NEOPLASMS, EXPERIMENTAL; RECEPTORS, NOTCH; TETRAHYDRONAPHTHALENES; VALINE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84901984072     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.25026     Document Type: Article

References (23)

1. Weng AP, Ferrando AA, Lee W, et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 2004; 306:269-271.
2. South AP, Cho RJ, Aster JC. The double-edged sword of Notch signaling in cancer. Semin Cell Dev Biol 2012; 23:458-464.
3. Shih I-M, Wang T-L. Notch signaling, γ-secretase inhibitors, and cancer therapy. Cancer Res 2007; 67:1879-1882.
4. Wei P, Walls M, Qiu M, et al. Evaluation of selective gamma-secretase inhibitor PF-03084014 for its antitumor efficacy and gastrointestinal safety to guide optimal clinical trial design. Mol Cancer Ther 2010; 9:1618-1628.
5. Brodney MA, Auperin DD, Becker SL, et al. Design, synthesis, and in vivo characterization of a novel series of tetralin amino imidazoles as gamma-secretase inhibitors: Discovery of PF-3084014. Bioorg Med Chem Lett 2011; 21:2637-2640.
6. Fan X, Matsui W, Khaki L, et al. Notch pathway inhibition depletes stem-like cells and blocks engraftment in embryonal brain tumors. Cancer Res 2006; 66:7445-7452.
7. Chen J, Kesari S, Rooney C, et al. Inhibition of notch signaling blocks growth of glioblastoma cell lines and tumor neurospheres. Genes Cancer 2010; 1:822-835.
8. Roma J, Masia A, Reventos J, et al. Notch pathway inhibition significantly reduces rhabdomyosarcoma invasiveness and mobility in vitro. Clin Cancer Res 2011; 17:505-513.
9. Baliko F, Bright T, Poon R, et al. Inhibition of notch signaling induces neural differentiation in Ewing sarcoma. Am J Pathol 2007; 170:1686-1694.
10. Engin F, Bertin T, Ma O, et al. Notch signaling contributes to the pathogenesis of human osteosarcomas. Hum Mol Genet 2009; 18:1464-1470.
11. Tanaka M, Setoguchi T, Hirotsu M, et al. Inhibition of Notch pathway prevents osteosarcoma growth by cell cycle regulation. Br J Cancer 2009; 100:1957-1965.
12. Zhang P, Yang Y, Nolo R, et al. Regulation of NOTCH signaling by reciprocal inhibition of HES1 and Deltex 1 and its role in osteosarcoma invasiveness. Oncogene 2010; 29:2916-2926.
13. Puget S, Grill J, Valent A, et al. Candidate genes on chromosome 9q 33-34 in volved in the progression of childhood ependymomas. J Clin Oncol 2009; 27:1884-1892.
14. Messersmith WA, LoRusso PM, Cleary JM, et al. A first-in-patient phase I study of the novel gamma secretase inhibitor PF-03084014 in patients with advanced solid tumor malignancies. Eur J Cancer 2012; 48:180. (Abstr #588).
15. Frgala T, Kalous O, Proffitt RT, et al. A fluorescence microplate cytotoxicity assay with a 4-log dynamic range that identifies synergistic drug combinations. Mol Cancer Ther 2007; 6:886-897.
16. Kang MH, Smith MA, Morton CL, et al. National Cancer Institute pediatric preclinical testing program: Model description for in vitro cytotoxicity testing. Pediatr Blood Cancer 2011; 56:239-249.
17. Houghton PJ, Morton CL, Tucker C, et al. The pediatric preclinical testing program: Description of models and early testing results. Pediatr Blood Cancer 2007; 49:928-940.
18. Keir ST, Morton CL, Billups C, et al. Initial testing of VNP40101M (Cloretazine®) by the pediatric preclinical testing program. Pediatr Blood Cancer 2008; 51:439-441.
19. Liem NL, Papa RA, Milross CG, et al. Characterization of childhood acute lymphoblastic leukemia xenograft models for the preclinical evaluation of new therapies. Blood 2004; 103:3905-3914.
20. Samon JB, Castillo-Martin M, Hadler M, et al. Preclinical analysis of the gamma-secretase inhibitor PF-03084014 in combination with glucocorticoids in T-cell acute lymphoblastic leukemia. Mol Cancer Ther 2012; 11:1565-1575.
21. Aster JC, Blacklow SC, Pear WS. Notch signalling in T-cell lymphoblastic leukaemia/lymphoma and other haematological malignancies. J Pathol 2010; 223:263-274.
22. Kolb EA, Gorlick R, Keir ST, et al. Initial testing (stage 1) by the pediatric preclinical testing program of RO4929097, a γ-secretase inhibitor targeting notch signaling. Pediatr Blood Cancer 2012; 58:815-818.
23. DeAngelo DJ, Stone RM, Silverman LB, et al. A phase I clinical trial of the notch inhibitor MK-0752 in patients with T-cell acute lymphoblastic leukemia/lymphoma (T-ALL) and other leukemias. J Clin Oncol 2006; 24(suppl 15):357s, abstr 6585.